Abstract -Preeclampsia is one of the leading causes of maternal and neonatal mortality and morbidity worldwide. We have previously reported that magnesium sulfate therapy is effective for early-onset (EO) preeclampsia. To investigate the molecular mechanisms underlying this favorable effect, metabolomics analysis of magnesium sulfate-treated preeclamptic placentas was performed using capillary electrophoresis time of flight mass spectrometry. There were significant metabolic differences between EO-preeclamptic placentas (n=7) and other placentas (late-onset preeclampsia [n=3], normal pregnancies [n=10]). In EO-preeclamptic placentas, the glutathione metabolism pathway was markedly upregulated, whereas single-sample gene-set enrichment analysis using a publicly available microarray dataset (GSE75010) showed that the glutathione metabolism pathway was significantly downregulated in EO-preeclamptic placentas compared with nonpreeclamptic controls. Metabolomic profiles showed that magnesium sulfate significantly promoted glutathione production in an immortalized trophoblast cell line under oxidative stress conditions but not under normal conditions. Magnesium sulfate suppressed hydrogen peroxide-induced production of reactive oxygen species. Exploratory analysis revealed that urinary 8-isoprostane was decreased in all 5 women treated with magnesium sulfate for preeclampsia with severe features. These findings suggest that magnesium sulfate is effective for treating EOpreeclampsia partly because of its antioxidant effects on trophoblasts. (Hypertension. 2019;73:671-679.
P reeclampsia affects 2% to 8% of pregnancies and is associated with maternal and neonatal mortality and morbidity. 1 Preeclampsia is a heterogeneous, pregnancy-specific syndrome clinically recognized by the development of hypertension and proteinuria. 1 It can be classified as either earlyonset (EO, <34 weeks gestation) or late-onset (LO, ≥34 weeks gestation) subtypes according to the gestational age at which clinical symptoms develop. [1] [2] [3] Accumulating evidence suggests that EO-preeclampsia develops because of poor placentation (placental preeclampsia), whereas LO-preeclampsia often occurs in women with latent maternal endothelial dysfunction (maternal preeclampsia). [1] [2] [3] Poor placentation and endothelial dysfunction sometimes coexist (eg, in women with a history of chronic hypertension), which is classified as superimposed preeclampsia (SIPE). 3 In clinical settings, preeclampsia has a diverse clinical spectrum, and the underlying mechanisms by which the pathological placenta contributes to the onset and progression of preeclampsia are largely unknown.
Currently, the only definitive treatment for preeclampsia remains delivery of the placenta. Magnesium sulfate (MgSO 4 ) is usually used for the prevention and treatment of seizures in patients with preeclampsia and eclampsia in the short term (<48 hours). In daily practice, however, the progression of EO-preeclampsia with severe features (severe EO-preeclampsia) is sometimes alleviated on administration of MgSO 4 . Our research group previously reported that longterm (≥48 hours) use of MgSO 4 for severe EO-preeclampsia could help slow the progression of preeclampsia. 4 However, the mechanisms responsible for this favorable effect remain poorly understood, and determining the potentially favorable effects of MgSO 4 on placentas represents an important research question.
Metabolomics, the newest omics technology, is defined as the comprehensive analysis of metabolites in a biological cell, tissue, organ, or organism. 5 Metabolites are the end products of transcription, translation, and proteome and are, therefore, highly relevant to the function and phenotype of biological systems. However, the potential relationship between metabolomic profiles and the pathogenesis of preeclampsia has not yet been fully elucidated. In the present study, metabolomics analysis of MgSO 4 -treated preeclampsia placentas was performed using capillary electrophoresis-time of flight mass spectrometry (CE-TOFMS). We believe that this study will contribute to elucidating the molecular mechanisms underlying preeclampsia pathogenesis and the effect of MgSO 4 on placentas.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Collection of Placentas
Tissue samples were collected from the central part of the placenta avoiding macroscopic areas of infarction and calcification. After briefly rinsing in saline, the samples were snap-frozen in liquid nitrogen for metabolomics analysis and stored at −80°C.
Placental Metabolomic Profiles
To investigate placental metabolomic profiles in normal and preeclampsia pregnancies, placental villous tissues from normal (n=10, cases 1-10) and preeclampsia with severe features (severe preeclampsia; n=10, cases [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] pregnancies were collected at Kyoto University Hospital, Japan. Severe preeclampsia was defined as a maternal systolic blood pressure ≥160 mm Hg or a diastolic blood pressure ≥110 mm Hg over 2 consecutive measurements taken at least 6 hours apart, as well as proteinuria ≥2 g/24 h after 20 weeks of gestation. Patient characteristics are presented in Table S1 in the online-only Data Supplement. All study participants in the control and preeclampsia groups gave birth by cesarean section. The 10 preeclampsia cases consisted of 6 EO-preeclampsia (cases 11-16), 3 LO-preeclampsia (cases [17] [18] [19] , and 1 EO-SIPE (case 20). All but 1 woman with preeclampsia underwent MgSO 4 treatment for >2 days.
Quantitative Real-Time PCR
Villous tissues were obtained from normal placentas at early (6-13 weeks), middle (16-25 weeks) , and late (37-38 weeks) gestation (n=6 in each group) to examine the expression of enzymes involved in glutathione synthesis using quantitative real-time polymerase chain reaction (PCR).
Cell Culture
An immortalized term trophoblast cell line 1 (TCL1), 6 kindly provided by S. Takeda (Juntendo University, Tokyo, Japan), was maintained in RPMI 1640 medium (Roswell Park Memorial Institute; Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humid atmosphere of 20% O 2 and 5% CO 2 .
Metabolomic Profiles and MgSO 4
To examine MgSO 4 -induced metabolomic alterations in trophoblasts, TCL1 cells were grown in 6-cm dishes and treated with or without MgSO 4 (8 mmol/L; Nacalai Tesque, Kyoto, Japan) for 2 hours (n=3 in each group). Moreover, to evaluate the effect of MgSO 4 under oxidative stress conditions, TCL1 cells were initially treated with or without MgSO 4 (8 mmol/L) for 1 hour, then further cultured with hydrogen peroxide (H 2 O 2 ; 100 µmol/L) for 1 hour (n=3 in each group).
Glutathione Synthesis Enzymes and MgSO 4
To examine MgSO 4 -induced alterations in the expression of glutathione synthesis enzymes, TCL1 cells were cultured in 12 well plates with or without MgSO 4 (4 or 8 mmol/L) for 24 hours. Experiments were performed 3× in duplicate.
Comprehensive Analysis of Metabolites
All CE-TOFMS experiments and the metabolome analysis were performed at Human Metabolome Technologies (HMT; Tsuruoka, Japan) as previously reported. 7 Peaks detected in the CE-TOFMS analysis were extracted using automatic integration software (MasterHands version 2.11.1.11, developed at Keio University) to obtain the mass-to-charge ratio (m/z), migration time, and peak area. All target metabolites were then assigned from HMT's standard library and known-unknown peak library on the basis of m/z and migration time. The tolerance was ±0.5 minutes in migration time and ±10 ppm in m/z. Peak areas were normalized against those of the internal standards; then the resultant relative area values were further normalized by sample amount. Measurement of the absolute quantities of 110 predetermined major metabolites in each sample was performed based on the peak area of internal controls of each metabolite.
Gene Expression Data Analysis
To investigate the regulation of the glutathione metabolism pathway in preeclampsia placentas, gene expression data (GSE75010) of control and preeclampsia placentas were obtained from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/gds/) as series matrix files. GSE75010 was chosen as it had the largest sample size (n=157) available at Gene Expression Omnibus DataSets. Single-sample gene-set enrichment analysis 8 was performed to generate gene-set activation scores of the KEGG_GLUTATHIONE_METABOLISM pathway, which we previously identified as 1 of 10 preeclampsia-specific pathways. 9 Of 157 placentas, 31 from pregnancies with a maximum systolic blood pressure ranging 140 to 160 mm Hg were excluded from further analysis. Enrichment scores of the KEGG_GLUTATHIONE_ METABOLISM pathway were compared between control pregnancies with delivery at <34 weeks (n=23), placentas of pregnancies with a systolic blood pressure ≥160 mm Hg and delivery at <34 weeks (n=44), control pregnancies with delivery at ≥34 weeks (n=30), and placentas of pregnancies with systolic blood pressure of ≥160 mm Hg and delivery at ≥34 weeks (n=29). 
Intracellular Reactive Oxygen Species Analysis

Quantitative Real-Time PCR
Total RNA extraction from placental tissues and TCL1 cells was performed using an RNeasy Mini kit (Ambion, Austin, TX) as previously described. 10 The forward and reverse primers used for cDNA amplification are presented in Table S2 . Quantitative real-time PCR was performed using SYBR premix ExtaqII (Takara Bio, Otsu, Japan) on the LightCycler 480 Real-Time PCR system (Roche Diagnostics, Mannheim, Germany). All data were normalised using GAPDH as an internal control, and results were expressed relative to controls.
Measurement of 8-Isoprostane Level
Measurement of 8-isoprostane, an oxidative stress biomarker, was performed to examine the effect of MgSO 4 on the level of systemic oxidative stress. Urine samples (n=19 samples from 5 women) were collected before and after initiation of MgSO 4 treatment for severe preeclampsia (including preeclampsia-like syndromes) and stored at −80°C until analysis. In addition, urine samples (n=10 samples from 4 women) were also obtained from non-MgSO 4 -treated women with hypertensive disorders of pregnancy without severe features. The pregnancy course and outcomes for the 9 cases are presented in Table S3 . The levels of urinary 8-isoprostane were measured using an 8-isoprostane ELISA kit (Detroit R&D, Detroit, MI). Results were expressed by creatinine to avoid the effect of urine volume fluctuation, where (8-isoprostane [pg/mL]: creatinine [mg/ml])=8-isoprostane (pg/mg creatinine), as described elsewhere.
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Statistical Analysis
Unsupervised hierarchical cluster analysis and heat map visualization were performed using PeakStat ver.3.18 (HMT). Principal component analysis was performed using SampleStat ver.3.14 (HMT). Factor loading was defined as the correlation coefficients between the principal component (PC) scores and the variables as previously described. 12 Metabolite network mapping was conducted using Visualization and Analysis of Networks containing Experimental Data. 13 Over-representation analysis was conducted to identify statistically significant metabolic pathways as metabolite set enrichment analysis. 12 Values for relative area or metabolite concentrations were compared using a Mann-Whitney U test. The results are presented as the mean±SD. The metabolomic data of glutathione precursors, quantitative real-time PCR of enzymes involved in glutathione synthesis, and results of intracellular ROS experiments are presented as the mean±SEM. These data were statistically analyzed by 1-way ANOVA followed by Tukey multiple comparisons test using Prism 6.1 (GraphPad Software, La Jolla, CA). A P of <0.05 was considered statistically significant.
The detail for the experiments was placed in the online-only Data Supplement.
Results
Placental Metabolomics Profile Can Discriminate Early-Onset Preeclampsia From LO-Preeclampsia and Normal Pregnancies
A total of 208 peaks were assigned to metabolites. Among them, glutathione was identified as having the highest fold change in preeclampsia placentas versus normal placentas ( Figure S1 ). Unsupervised hierarchical cluster analysis clearly separated EO-preeclampsia placentas from placentas derived from LO-preeclampsia, EO-SIPE, and normal pregnancies ( Figure 1A ). The levels of 42 metabolites were found to be significantly different between EO-preeclampsia and other placentas (Table S4 ). The principal component analysis confirmed the existence of 2 distinct subpopulations, the EO group (including EO-SIPE) and the other group consisting of LO-preeclampsia and normal pregnancies ( Figure 1B) . As the placentas could be metabolically divided into 2 groups according to the values of PC2, 53 significant metabolites were selected according to the significance of factor loading in PC2 (Table) . An over-representation analysis was performed for 15 metabolites that showed large positive factor loadings in PC2, and the creatine metabolism pathway was identified as a significantly enriched metabolic pathway in the EO group ( Figure S2) . However, over-representation analysis using 38 metabolites that had large negative factor loadings in PC2 revealed the ribonucleotide and purine metabolism pathways as being significantly enriched metabolic pathways in LO-preeclampsia and normal pregnancies ( Figure S2 ). Although metabolite set enrichment analysis identified the creatine metabolism pathway as a potential candidate enriched in the EO group, its Q value was too large (q=0.543). In the current analysis, metabolite set enrichment analysis did not shed light on the glutathione metabolism pathway as this pathway was not included in the metabolite set enrichment analysis datasets of HMT. However, glutathione had the highest fold change (69.7) in EO-preeclampsia placentas when compared with the other placentas. Furthermore, cysteine (Cys), which is a key determinant of glutathione synthesis, was ranked second (8.1; Table S3 ), and both Cys and glutathione were significantly elevated in EO-preeclampsia and EO-SIPE placentas compared with normal and LO-preeclampsia placentas ( Figure  S3 ). Indeed, Cys and glutathione were ranked first and second as metabolites with large positive factor loadings in PC2 (Table) . Intriguingly, glutathione, one of the major intracellular antioxidants, is known to be decreased in preeclampsia placentas, [14] [15] [16] [17] which is in stark contrast to our findings.
Gene Expression Profiling Analysis of the Glutathione Metabolism Pathway in Placentas
To confirm whether the glutathione metabolism pathway is generally downregulated in EO-preeclampsia placentas, single-sample gene-set enrichment analysis was performed using the largest publicly available microarray dataset of preeclampsia placentas. The analysis revealed that the enrichment scores of the KEGG_GLUTATHIONE_ METABOLISM pathway were significantly lower in the placentas of women with severe preeclampsia who delivered before 34 weeks of gestation compared with those of controls (<34 weeks), although they were similar among placentas of EO-preeclampsia, LO-preeclampsia, and controls from pregnancies with deliveries after 34 weeks ( Figure S4 ). Because this gene expression profiling analysis was also in contrast to the metabolomic profiles of placentas showing marked elevation of glutathione, we then focused on investigating the causal mechanisms underlying the enhanced placental glutathione synthesis observed in EO-preeclampsia cases managed at our hospital.
MgSO 4 Induces Distinct Metabolomic Profiles in Trophoblasts Under Normal and Oxidative Conditions
As our institution introduced long-term (over 48 hours) use of MgSO 4 in expectant management for severe EO-preeclampsia, 4 in the present study, 9 of 10 women with preeclampsia had undergone MgSO 4 treatment for >2 days. Although the duration of MgSO 4 therapy was not correlated with placental glutathione levels (data not shown), we hypothesized that MgSO 4 therapy could upregulate the glutathione metabolism pathway in placentas. Comprehensive analysis of intracellular metabolites was performed to evaluate the influence of MgSO 4 in TCL1 cells under normal and oxidative conditions. A total of 174 peaks were assigned to metabolites. Two groups of samples (control and MgSO 4 -treated) were clearly distinct in PC2, and 7 metabolites were selected by factor loading in PC2 (P<0.01; Figure 2A) Figure 2B ). 
MgSO 4 Affects the Production of Glutathione Precursors
Glutathione is a tripeptide composed of 3 amino acids: Glu, Cys, and glycine (Gly). Therefore, the metabolomic data of these precursors were extracted to determine MgSO 4 treatment-induced changes in metabolite state in the presence or absence of oxidative stress. Glu levels were significantly elevated in MgSO 4 -treated TCL1 cells in the presence of enhanced the production of γ-Glu-Cys under oxidative stress conditions, leading to an increase in glutathione levels in trophoblasts.
Glutathione Enzyme Levels (Glutathione Cysteine Ligase Catalytic Subunit, Glutathione Cysteine Ligase Modulate Subunit, Glutathione Synthase) in Trophoblasts and Placentas
In glutathione biosynthesis, as shown in Figure 3 , GCLC (glutathione cysteine ligase catalytic subunit) and GCLM (glutathione cysteine ligase modulate subunit) catalyze the first step, and GSS (glutathione synthase) catalyzes the second step. As the production of γ-Glu-Cys and glutathione is regulated by these enzymes, the effect of MgSO 4 on the mRNA expression of these glutathione enzymes was investigated in TCL1 cells. Both GCLC and GCLM mRNA levels were significantly augmented by MgSO 4 (8 mmol/L; P<0.05 and P<0.01, respectively; Figure 4A ), whereas MgSO 4 had no effect on the level of GSS expression ( Figure 4A ). This suggests that the observed elevation in glutathione induced by MgSO 4 can be attributed to increased γ-Glu-Cys via upregulated GCLC and GCLM expression. The levels of glutathione enzymes in the placentas of normal and preeclampsia pregnancies were then investigated. The results showed a significant increase in GCLC, GCLM, and GSS mRNA levels at 37 to 38 weeks gestation ( Figure 4B ). In contrast, GCLC expression was significantly elevated in EO and EO-SIPE placentas compared to LO-preeclampsia and controls (normal term pregnancy; Figure 4C ). GCLM and GSS mRNA levels were not different between normal and preeclampsia placentas ( Figure 4C ). Considering that most women with EO-preeclampsia underwent long-term MgSO 4 therapy at our institution, these findings also indicate that MgSO 4 therapy is associated with an increase in γ-Glu-Cys and subsequent glutathione production through upregulated GCLC and GCLM expression.
MgSO 4 Represses ROS Production Under Oxidative Stress Conditions
The antioxidant activity of MgSO 4 was investigated in TCL1 cells. H 2 O 2 -induced ROS generation was significantly suppressed by MgSO 4 (4 mmol/L, P<0.05; 8 mmol/L, P<0.01; Figure 5A ).
MgSO 4 Treatment Alleviates Oxidative Stress in Pregnancies Complicated by Early-Onset Preeclampsia
Finally, we tested the effect of MgSO 4 against oxidative stress associated with preeclampsia. Creatinine-adjusted urinary 8-isoprostane levels, which are used as a representative marker of lipid oxidative stress, were decreased in all 5 cases within 4 days after initiation of MgSO 4 treatment ( Figure 5B ). Case 1 presented hypertension and proteinuria as early as 16 weeks gestation. This case was complicated by ascites and pleural effusion at 19 weeks, but these symptoms disappeared after termination of the pregnancy. Although this case did not meet the diagnostic criteria for preeclampsia, we included this case for analysis because the underlying mechanisms must be similar to EO-preeclampsia. In cases 2, 3, 4, and 5, creatinine-adjusted urinary 8-isoprostane levels decreased to less than half of the initial level. Prolongation of pregnancy by ≈4 weeks was achieved in cases 2 and 3, owing to stable maternal conditions. In contrast, the levels of 8-isoprostane did not change much in non-MgSO 4 -treated women who had 4 on levels of glutathione (GSH) synthesis enzymes. In GSH biosynthesis, GCLC and GCLM catalyze the first step, and GSS catalyzes the second step. Both GCLC and GCLM expression levels in trophoblast cell line 1 cells were significantly increased by MgSO 4 treatment (8 mmol/L; n=3) . B, Expression of GSH synthesis enzymes in normal placentas collected at early, middle, and late gestation (n=6 in each group). C, GSH synthesis enzyme levels in normal and preeclamptic placentas. Control, normal term placenta (cases 1-10); EO-PE, cases 11-16; EO-SIPE, case 20; LO-PE, cases 18 and 19. The data for case 17 was not available because the sample was lost. *P<0.05, **P<0.01. EO indicates early onset; LO, late onset; ns, nonsignificant; PE, preeclampsia; and SIPE, superimposed preeclampsia.
no exacerbation of hypertension (cases 6, 7, and 8). In case 9, urinary 8-isoprostane levels more than doubled from 31 to 32 weeks, when severe preeclampsia developed and MgSO 4 therapy was eventually started. These findings suggest that MgSO 4 treatment alleviates oxidative stress state in pregnancies complicated by EO-preeclampsia.
Discussion
The present study is, to the best of our knowledge, the first to demonstrate that global metabolite profiling of the placenta can discriminate EO-preeclampsia from both LO-preeclampsia and normal pregnancies using a CE-TOFMS technique. We also found that MgSO 4 treatment significantly augmented glutathione levels and suppressed ROS production in trophoblasts under oxidative stress conditions.
Placental Metabolomics Profile of Preeclampsia
It has been postulated that EO-preeclampsia and LO-preeclampsia have distinct pathogenesis; however, most cDNA microarray-based gene profiling studies of placentas fail to distinguish one from the other by unsupervised clustering methods. 9 We first demonstrated that EO-preeclampsia placentas are clearly distinct from other placentas. To date, there has been only 1 report of global metabolite profiling of preeclampsia placentas in which nuclear magnetic resonance-based metabolomics were performed. 18, 19 However, the nuclear magnetic resonance-based metabolomics study identified only 25 metabolites in the placenta, and glutathione was not included among them. 18 However, the present study by mass spectrometry-based metabolomics yielded as many as 208 metabolites in placentas. Mass spectrometry methods, such as CE-TOFMS, have a relatively high sensitivity compared with nuclear magnetic resonance methodology, [19] [20] [21] and hence the marked elevation in glutathione production was first identified in EO-preeclampsia placentas.
Glutathione Levels in EO-Preeclampsia Placentas
Oxidative stress has been proposed as one of the underlying factors involved in the pathophysiology of preeclampsia, especially in EO-preeclampsia. [1] [2] [3] To date, most studies, [14] [15] [16] [17] but not all, 22 have found that glutathione levels are decreased in preeclampsia placentas. Moreover, transcriptomics and proteomics studies have also shown that glutathione metabolism dysfunction is the underlying pathogenesis for preeclampsia. 9, 23 Gene expression profiling analysis of the largest recent microarray dataset also confirmed that the glutathione metabolism pathway was downregulated in EO-preeclampsia placentas. Because glutathione is known to be an essential endogenous antioxidant, its downregulation could be implicated in placental susceptibility to oxidative stress. Interestingly, however, the present study demonstrated extraordinarily high levels of glutathione in EO-preeclampsia placentas. This may be explained by the fact that glutathione requires magnesium for its synthesis, 24 and long-term (usually >48 hours) use of MgSO 4 has been applied for severe preeclampsia in our institution.
Enhanced Glutathione Production by MgSO 4 in Oxidative Stress Conditions
This is the first study to show that MgSO 4 significantly promoted glutathione production in trophoblasts when cultured under oxidative stress conditions. Dietary magnesium intake is inversely associated with cardiovascular disease risk. 25 Animal studies have shown that magnesium deficiency is associated with disruptions in the antioxidant defense system, which is mainly because of glutathione depletion. 26 In addition, magnesium treatment is found to be efficient in restoring renal and testis glutathione levels in a mouse model of cadmium-induced oxidative damage. 27 Although the precise mechanism through which Mg 2+ triggers intracellular signaling cascades remains unclear, MgSO 4 increased glutathione synthesis enzyme levels. Furthermore, there would probably be antioxidative defense mechanisms other than increasing synthesis of glutathione, such as inhibition of lipid peroxidation by the possible interactions of free radicals with the MgSO 4 molecular structures. 28 These studies are strongly suggestive that magnesium is linked to oxidative stress. In clinical practice, MgSO 4 is effective in ameliorating severe EO-preeclampsia in some patients, but not in others. MgSO 4 therapy dramatically stabilized pregnancies in preeclampsia patients with higher levels of urinary 8-isoprostane. Collectively, these findings indicate that MgSO 4 exerts antioxidant effects according to the level of oxidative stress and that EO-preeclampsia patients with higher levels of oxidative stress can be a good candidate for MgSO 4 therapy.
Limitations
There are a few limitations with the design of this study. First, the gestational age differed between EO-preeclampsia and normal controls, which might have influenced the distinct metabolomic profiles seen between EO-preeclampsia placentas and the others. However, placentas obtained before 34 weeks are not generally considered normal because placentas can be affected by pathological mechanisms accompanied by preterm delivery. Second, our study did not include EO-preeclampsia pregnancies that were not treated with MgSO 4 . However, it is already well established that expectant management for EO-preeclampsia benefits the infant and that MgSO 4 use prevents eclampsia in severe preeclampsia. 29 In this context, severe EO-preeclampsia was always managed with MgSO 4 administration. Further investigation is warranted to ascertain whether long-term use of MgSO 4 for EO-preeclampsia benefits the mother and baby in a large, prospective, randomized, multicentre study.
In conclusion, this global metabolomics analysis of placentas showed that EO-preeclampsia placentas were metabolically different from other placentas and that the glutathione metabolism pathway was markedly upregulated in MgSO 4 -treated EO-preeclampsia placentas. In addition, metabolomics analysis of a trophoblast cell line revealed that MgSO 4 enhanced the glutathione metabolism pathway under oxidative stress conditions, which provides insight into precision medicine treatment approaches for EO-preeclampsia.
Perspectives
Preeclampsia remains a major cause of maternal mortality and morbidity worldwide, and the only definitive treatment for preeclampsia is termination of pregnancy. We first demonstrate the potential translational value of metabolomics in the field of preeclampsia. According to our results, MgSO 4 exerts its antioxidant effects on trophoblasts under oxidative stress conditions, but not under normal conditions, and, therefore, longterm use of MgSO 4 for patients with higher levels of oxidative stress could be a therapeutic strategy for EO-preeclampsia. The so-called pharmaco-metabolomic approach will help predict drug effectiveness for preeclampsia according to the individual metabolomic characteristics in future.
• Urinary 8-isoprostan, an oxidative stress biomarker, is decreased in women treated with MgSO 4 for severe EO-PE.
What Is Relevant?
• We have demonstrated that MgSO4 can enhance the glutathione metabolism pathway in trophoblasts under oxidative stress conditions, indicating that MgSO4 treatment alleviates placental oxidative stress and exerts favorable effect on pregnancies complicated by EO-PE.
• Long-term (≥48 hours) use of MgSO4 for patients with higher levels of oxidative stress could be a therapeutic strategy for EO-PE.
Summary
We investigated the placental metabolomic profile in normal and PE pregnancies, as well as the pharmacological action of MgSO 4 on trophoblasts using capillary electrophoresis-time of flight mass spectrometry. Global metabolite profiling of the placenta revealed that EO-PE was metabolically different from both late-onset PE and normal pregnancies and that the glutathione metabolism pathway was markedly upregulated in MgSO 4 -treated EO-PE placentas. In addition, MgSO 4 enhanced the glutathione metabolism pathway and suppressed reactive oxygen species production in trophoblasts under oxidative stress conditions. Furthermore, MgSO 4 treatment decreased the levels of urinary 8-isoprostane, an oxidative stress biomarker, in pregnancies complicated by severe EO-PE.
